ReviewFrontiers in medicine2026
Recombinant humanized type VII collagen for skin repair and regeneration: prospects for reconstructing the dermal-epidermal junction.
Review in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type VII collagen (Col VII) is a key component of the anchoring fibrils at the dermal-epidermal junction (DEJ). It plays a crucial role in maintaining stable adhesion between the epidermis and dermis, promoting wound re-epithelialization, and ensuring the structural integrity of the skin following repair. With advancements in genetic engineering, synthetic biology, and recombinant protein expression technologies, recombinant humanized type VII collagen (rhCol VII) has gradually emerged as a novel functional biomaterial of interest in the fields of skin repair and regenerative medicine. Compared with traditional type I and type III collagen materials, the potential advantages of rhCol VII lie in its excellent safety profile, scalability for industrial production, and its potential structural and functional targeting of the DEJ, which may offer new insights into restoring interface stability following wound repair. This review summarizes the molecular structure, biological functions, and recent therapeutic research progress of Col VII, as well as the application prospects of rhCol VII in chronic wounds, post-aesthetic surgery barrier damage, and tissue-engineered skin. It also discusses the challenges that remain to be addressed in material development and clinical translation, with the aim of providing a reference for further research on rhCol VII-based skin repair materials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.